Drugs / EGFR/B7H3 CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05341492 | May 2022 → May 2030 expected | triple-negative breast carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGFR/B7H3 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05341492 ↗ |
| Modality | Cell therapy | “2 × 10\^6/kg CAR-T cells” NCT05341492 ↗ |